Xspray Pharma Signs License Agreement with Handa Therapeutics – to Receive up to Double-Digit Royalty on Handa's Net Proceeds
STOCKHOLM, August 12, 2025--(BUSINESS WIRE)--This is the first out-licensing from Xspray's broad patent portfolio and marks an important milestone in capitalizing on its intellectual property assets. The company's core strategy to develop and commercialize improved PKI-drugs using its patented HyNap technology remains unchanged. Its lead product candidate Dasynoc awaits FDA-approval with a PDUFA date of October 7, 2025. However, further licensing agreements may be considered on a case-by-case basis.
"The agreement confirms the value of our patent portfolio and demonstrates that our long-term work to build our comprehensive patent portfolio is paying off. As for the dasatinib market, I'm convinced that when Dasynoc is launched it will be seen as the premium product in its market segment as it combines pH-independent absorption with lower dose strength and high precision, eliminating sensitivity to all acid-reducing agents," says Per Andersson, CEO of Xspray Pharma.
The agreement further ensures that Xspray's planned launch of Dasynoc can proceed without being affected by any United States regulatory exclusivities that may be associated with Handa's product. Handa's dasatinib product has not yet been launched.
About Xspray Pharma
Xspray Pharma AB (publ) is a pharmaceutical company focused on the development of improved PKIs for cancer treatment, leveraging its proprietary HyNap™ technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Xspray Pharma's shares are traded at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY). For more information about Xspray Pharma AB and its innovative approach to cancer treatment, please visit www.xspraypharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250812575897/en/
Contacts
For further information, please contact: Jacob Nyberg, IRXspray Pharma AB (publ)Tel: + 46 (0) 70 767 08 83E-mail: ir@xspray.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Growvana and Kudos Networks Announce Strategic Partnership to Empower Asian Brands in U.S. Retail
CHICAGO--(BUSINESS WIRE)-- Growvana, a leading advanced e-commerce enablement platform, has partnered with Kudos Networks, a global retail enablement firm, to expand Growvana's reach into the Chinese market and help Asian manufacturers succeed in U.S. e-commerce. This collaboration brings together Growvana's proven marketplace infrastructure and Kudos's strong network of trusted Asian brands to accelerate onboarding into Amazon Vendor Central and beyond. 'With Kudos Networks, we're unlocking access to some of the fastest-growing brands in Asia,' said Rohan Thambrahalli, founder and president of Growvana. 'Their deep roots and reputation in the region align perfectly with our mission to help brands grow faster, reduce operational friction, and drive profitability on marketplaces. While tariffs have created uncertainty, many leading Asian brands see this as an opportunity to expand their U.S. presence and get ahead of competitors worldwide.' Growvana enables qualified Seller Central brands to gain the benefits typically exclusive to direct vendors of prominent U.S. retailers—without the complexities of becoming an actual vendor or supplier. Through predictive inventory analytics, effortless one-click digital onboarding, and integrated financing, Growvana streamlines operations, reduces costs, and accelerates revenue growth. Additionally, Growvana's partnership with Kudos unlocks a vast ecosystem of brands and manufacturers, further fueling expansion in key international categories such as home goods, consumer electronics, and lifestyle products. 'Kudos is proud to be a bridge between world-class Asian manufacturers and the U.S. retail landscape,' said Miles Chen, founder of Kudos Networks. 'Growvana's platform gives our clients a clear path to scale on Vendor Central and with retailers like Target, Best Buy, and Home Depot. We're excited to collaborate and drive success for brands ready to expand globally.' Chen also pointed to economic volatility and tariffs as a key reason the partnership is timely. 'Tariffs are a factor impacting many Chinese and other Asian companies,' he said. 'But risk and opportunity always come together. The U.S. remains the most robust consumer market in the world—and Chinese manufacturers know the time to move is now. If others are stepping back, this is the moment for bold brands to step forward.' Together, Growvana and Kudos will co-develop onboarding programs, coordinate brand communications, and help Asian companies diversify from Seller Central to Vendor Central. This strategy has become increasingly attractive as Amazon's third-party environment grows more competitive. Brands and manufacturers interested in expanding into the U.S. are encouraged to connect with Growvana and Kudos to explore how this new partnership can accelerate their growth. For more information visit About Growvana Growvana is a next-generation e-commerce platform specifically designed to empower marketplace sellers with the advantages typically reserved for direct vendors of leading U.S. retailers—without the traditional vendor complexities. The platform accelerates revenue recognition cycles, optimizes operational costs, and provides powerful predictive inventory forecasts driven by real-time insights into revenue, inventory, and profitability. By significantly reducing operational risks and unlocking innovative business models, Growvana helps Seller Central brands scale profitably. About Kudos Networks KUDOS NETWORKS is a cross-border service provider specializing in North American retail channel development and brand operations. With a team of seasoned professionals—many boasting over 20 years of retail industry expertise—we have forged strong partnerships with top North American retailers, including Walmart, Target, Home Depot and Lowe's. As an official partner of Walmart and Target, we empower brands with end-to-end solutions, from online platform integration to offline retail expansion, ensuring seamless localization and sustainable growth in the North American market.
Business Wire
an hour ago
- Business Wire
Artera Receives U.S. FDA De Novo Marketing Authorization for AI-Digital Pathology Software Revolutionizing Prostate Cancer Care
SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for ArteraAI Prostate, establishing it as the first and only AI-powered software authorized to prognosticate long-term outcomes for patients with non-metastatic prostate cancer. ArteraAI Prostate is now recognized as an FDA-regulated Software as a Medical Device (SaMD). The technology's De Novo authorization establishes a new product code category for future AI-powered digital pathology risk-stratification tools, and enables its implementation at the point of diagnosis at qualified pathology labs in the U.S. This capability addresses a critical gap in prostate cancer care by reducing delays in delivering actionable insights at diagnosis, helping clinicians and patients make informed treatment decisions with greater confidence. 'This is a defining moment for AI in cancer care,' said Andre Esteva, CEO and co-founder of Artera. 'The FDA's decision validates the power of our MMAI platform to deliver on our vision to create AI-guided tools that enable data-backed and tailored treatments for each patient, leading to more confidence throughout the cancer journey, and ultimately, save more lives.' 'This approval highlights the groundswell of excitement surrounding the incorporation of AI into clinical practice flows. We need to utilize deep learning AI models to augment and better refine what a pathologist is able to report and Artera is leading the charge,' said Dr. Adam Cole, Founder and CSO at TruCore Pathology Group. 'As the demand for pathology services continues to outpace available capacity, tools like ArteraAI Prostate are critical. Implementing this software enhances our ability to deliver personalized insights more quickly, improves workflow efficiency, and allows us to scale services while increasing the quality of care.' Earning FDA De Novo authorization is a rare achievement, designed for novel medical innovations. This accomplishment marks yet another milestone for Artera, spotlighting its leadership and unwavering commitment to scientific rigor and excellence. Notably, the FDA authorization includes a Predetermined Change Control Plan, granting Artera the ability to expand platform capabilities through validating compatibility with additional digital pathology scanners without requiring further 510(k) submissions. The De Novo authorization for ArteraAI Prostate follows its earlier Breakthrough Device Designation. While the De Novo authorization applies specifically to the ArteraAI Prostate medical device software, Artera's underlying MMAI platform is also commercially available through the ArteraAI Prostate Test, as a Laboratory Developed Test (LDT). With this milestone, Artera continues to expand its pipeline of MMAI-powered software to support personalized cancer care. To learn more, visit About Artera Artera is a global leader in precision medicine, leveraging multimodal artificial intelligence (MMAI) to personalize cancer care. Artera's MMAI platform leverages a patient's digitized biopsy images along with the patient's clinical data to determine cancer aggressiveness and predict therapy benefit. This approach has been validated in multiple Phase 3 randomized trials, across different cancers, and is available in multiple versions across the globe. Artera's flagship product, the ArteraAI Prostate Test, is commercially available as a laboratory-developed test in the US and internationally through its distribution partners. The ArteraAI Prostate Test is the first of its kind to deliver both prognostic and predictive insights for patients with prostate cancer, empowering clinicians and patients to make more informed treatment decisions. Additional MMAI-powered products include the ArteraAI Breast Test (UKCA), the ArteraAI Prostate Biopsy Assay (UKCA), and ArteraAI Prostate (FDA). Artera has regulatory authorization for its medical device product in the US and UK. Artera's headquarters is based in Los Altos, California, while its CLIA-certified and clinical laboratory is located in Jacksonville, Florida. For more information about Artera, visit
Newsweek
an hour ago
- Newsweek
Nationwide Coffee Recall as Products May Contain Glass
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Dollar General Corporation has recalled select lots of its Clover Valley Instant Coffee products sold nationwide over concerns they may contain glass fragments. The recalled products were sold and distributed exclusively in Dollar General stores between July 9 and 21, the company said in an announcement published by the U.S. Food and Drug Administration (FDA). Newsweek contacted Dollar General Corporation for comment via email outside of regular office hours. Stock image. Dollar General Corporation has recalled select lots of its Clover Valley Instant Coffee products over concerns of glass contamination. Stock image. Dollar General Corporation has recalled select lots of its Clover Valley Instant Coffee products over concerns of glass contamination. Lino Mirgeler/picture-alliance/dpa/AP Why It Matters The FDA said that ingesting glass fragments "may cause injury to the consumer." "These injuries may include damage to teeth, laceration of the mouth and throat, or perforation of the intestine," it said. What To Know The recall applies to three lots of Dollar General's eight ounce Clover Valley Instant Coffee, with the UPC code: 876941004069. The affected lot numbers and best-by dates are the following: L-5163 - best-by: 12/13/2026 L-5164 - best-by: 12/13/2026 L-5165 - best-by: 12/14/2026 The recalled products were sold and distributed in every state other than Alaska and Hawaii, the FDA said. The recall was initiated after a customer notified Dollar General about the potential issue. As of August 12, no illnesses or injuries had been reported in connection with the products. The company said it was investigating the source of the glass contamination. It also encouraged customers who purchased the affected products to discard them and contact the company for a full refund. What People Are Saying Dollar General Corporation said in a recall announcement that it is "investigating the source of the glass contamination and apologizes for any inconvenience caused." Dr. Mark Fischer, regional medical director at International SOS, told Newsweek previously: "It can be dangerous to consume metals or other foreign objects found in food... [They] can cause cuts or internal injury and may need to be removed via a surgical procedure. If you swallow any foreign objects, it's best to consult a healthcare professional." What Happens Next Dollar General said it was investigating the source of the glass contamination. FDA inspectors are expected to carry out a hazard assessment before issuing one of three risk levels. The three classifications are:
